NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Announces Poster Presentation at the Neuroimmunology Drug Development Summit in Boston
INmune Bio (NASDAQ: INMB) this morning announced that Christopher Barnum, Ph.D., Director of Neuroscience and Translational Medicine, will be presenting a poster at the Neuroimmunology Drug Development Summit taking place in Boston on April 17th. The poster presentation is titled “Phase 1b open-label, biomarker-directed study of the brain penetrant, soluble selective inhibitor of soluble tumor necrosis factor (TNF) XPro1595 in patients with mild to moderate Alzheimer’s disease.” The presentation will highlight INmune’s drug candidate XPro1595 which targets neuroinflammation, a cause of microglial activation and neuronal cell death. “Because of our focus on neuroinflammation as a cause of neurologic disease, we…







